{"analyses":[{"ciLowerLimit":"1.8113","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.9177","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"2.2989","statisticalMethod":"Chi-squared","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1501"},{"groupId":"OG001","value":"1681"}]}],"title":"30 MIU/day"},{"categories":[{"measurements":[{"groupId":"OG000","value":"771"},{"groupId":"OG001","value":"1985"}]}],"title":"48 MIU/day"}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"568"},{"groupId":"OG001","value":"857"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"2272"},{"groupId":"OG001","value":"3666"}],"units":"cycles"}],"description":"Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.","groups":[{"description":"Cancer patients weighing \\<=65kg treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006: <=65kg"},{"description":"Cancer patients weighing \\>65kg treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG001","title":"EP2006: >65kg"}],"paramType":"NUMBER","populationDescription":"All cycles treated","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"EP2006 Dose by Patient Weight: Cycle Level","type":"PRIMARY","typeUnitsAnalyzed":"cycles","unitOfMeasure":"cycles"}